News | Remote Monitoring | August 31, 2018

Philips Acquires Xhale Assurance Inc.

Addition of Xhale’s disposable pulse oximetry sensor expands Philips’ monitoring and analytics business

Philips Acquires Xhale Assurance Inc.

August 31, 2018 — Philips announced it has acquired Xhale Assurance Inc., a U.S.-based scale-up company developing and commercializing next-generation sensor technologies. Xhale Assurance’s disposable pulse oximetry sensor is placed on the wing (ala) of the nose, and can reliably measure and transmit a patient’s heart rate and blood oxygenation under low-perfusion conditions that are challenging for conventional fingertip pulse oximetry sensors. Philips said this technology will broaden and differentiate its existing portfolio of oxygen saturation monitoring solutions and allow the company to expand into a currently underserved clinical segment. Financial details of the transaction were not disclosed.

Xhale Assurance’s alar sensor allows accurate measurement at lower oxygen saturation levels, which is essential for patients who have suffered a heart attack or a hypoxic event. As such, the sensor enhances patient safety by overcoming the shortcomings of existing oxygen saturation sensors, and can provide caregivers with early warning signals of impending adverse events.

Philips’ patient monitoring portfolio addresses all acuity levels and care settings within hospitals and health systems, and supports a broad patient population – from basic screening to complex surveillance in critical care. It includes bedside and wearable patient monitors, consumables such as connected wearable biosensors, and clinical decision support tools and mobile applications for real-time clinical information at the patient’s bedside.

For more information: www.usa.philips.com/healthcare

Related Content

Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
High Intensity Exercise in Teenagers Could Ward Off Heart Disease

Ultrasound image of the carotid artery. Lines in yellow were used to determine arterial diameter and stretching before and following exercise.

News | Cardiac Diagnostics | July 16, 2018
New research published in Experimental Physiology has indicated potential differences in heart health benefits of...
News | Cardiac Diagnostics | June 14, 2018
A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the...
The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

 

Feature | Cardiac Diagnostics | May 07, 2018 | Steven D. Freedman, M.D., Ph.D.
 
Overlay Init